Cargando…

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia

The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML). Moreover, fms like tyrosine kinase 3 (FLT3) growth factor signaling pathways i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seipel, Katja, Marques, Miguel A. T., Sidler, Corinne, Mueller, Beatrice U., Pabst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025168/ https://www.ncbi.nlm.nih.gov/pubmed/29857559 http://dx.doi.org/10.3390/cancers10060170

Ejemplares similares

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Seipel, Katja, et al.
Publicado: (2018)

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
por: Lehmann, Christian, et al.
Publicado: (2016)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
por: Zhu, Haohao, et al.
Publicado: (2022)

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019)

Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017)

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment: Miniperspective
por: Zhao, Yujun, et al.
Publicado: (2014)

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2022)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2019)

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
por: Mascarenhas, John, et al.
Publicado: (2022)

8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction
por: Pettersson, Mariell, et al.
Publicado: (2015)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
por: Khurana, Arushi, et al.
Publicado: (2019)

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
por: Italiano, Antoine, et al.
Publicado: (2021)

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
por: Costa, Barbara, et al.
Publicado: (2013)

Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
por: Beloglazkina, Anastasia, et al.
Publicado: (2020)

Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction
por: Pettersson, Mariell, et al.
Publicado: (2015)

An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors
por: Xue, Xin, et al.
Publicado: (2018)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
por: Yuan, Yuan, et al.
Publicado: (2011)

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
por: Miles, Xanthene, et al.
Publicado: (2021)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
por: Jiang, Liren, et al.
Publicado: (2019)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes
por: Lulli, Daniela, et al.
Publicado: (2017)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

The p53 Inhibitor MDM2 Facilitates Sonic Hedgehog-Mediated Tumorigenesis and Influences Cerebellar Foliation
por: Malek, Reem, et al.
Publicado: (2011)

Design, Synthesis and Biological Evaluation of Sulfamide and Triazole Benzodiazepines as Novel p53-MDM2 Inhibitors
por: Yu, Zhiliang, et al.
Publicado: (2014)

Binding Ensembles of p53-MDM2 Peptide Inhibitors by Combining Bayesian Inference and Atomistic Simulations
por: Lang, Lijun, et al.
Publicado: (2021)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
por: Coffill, Cynthia R., et al.
Publicado: (2016)

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions
por: Blackburn, Tim J., et al.
Publicado: (2013)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III
por: Witkowski, Jakub, et al.
Publicado: (2023)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II
por: Witkowski, Jakub, et al.
Publicado: (2022)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I
por: Witkowski, Jakub, et al.
Publicado: (2022)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light
por: Hansen, Mickel J., et al.
Publicado: (2018)

Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an (18)F-Labeled Analogue of the MDM2 Inhibitor SP-141
por: Chitneni, Satish K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hrokb28623rkbdqor2b14inu4j